

## Certificate of Analysis

### FGR, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-568, 14-568-K, 14-568M

Parent Lot # 1603539

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** N-terminal 6His-tagged, recombinant, human FGR, amino acids 2–end expressed by baculovirus in Sf21 insect cells. Purified using Ni<sup>2+</sup>/NTA-agarose. Purity 79.7% by SDS-PAGE and Coomassie blue staining. MW = 60.4kDa.

**Formulation:** 1.109mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.

**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.


**Specific Activity (Parent lot# 1603539):** 2800U/mg, where one unit of FGR, active activity is defined as 1nmol phosphate incorporated into 0.1mg/ml poly(Glu, Tyr) (4:1) per minute at 30°C with a final ATP concentration of 100µM.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C


**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**

### Quality Control Testing

**Kinase Assay:** 0.4–5.6ng of this lot of enzyme phosphorylated 0.1mg/ml poly(Glu, Tyr) (4:1) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



**MS Tryptic Fingerprint:** Confirmed product identity as FGR with the translated sequence listed on page three.



## Certificate of Analysis

### Kinase Assay Protocol

#### Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Poly(Glu, Tyr) (4:1):** Use at a final assay concentration of 0.1mg/ml. Prepare a 1mg/ml stock and add 2.5µl of stock per assay point.
3. **FGR, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 5% glycerol, 2-mercaptoethanol, 1mg/ml BSA. Use 0.4–5.6ng per assay point.
4. **[ $\gamma$ -<sup>33</sup>P]ATP:** 2.5 x magnesium acetate/[ $\alpha$ -<sup>33</sup>P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [ $\gamma$ -<sup>33</sup>P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

#### Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer to wells.
2. Add 2.5µl of **poly(Glu, Tyr) (4:1)**.
3. Add **2.5µl (0.4–5.6ng) FGR, active**.
4. Add 5µl of dH<sub>2</sub>O.
5. Add 10µl of diluted [ $\gamma$ -<sup>33</sup>P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **Filtermat A**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

## Certificate of Analysis

### FGR Sequence Information

<b><u>Protein</u></b>	Human FGR
<b><u>Tags</u></b>	N-Terminal 6His
<b><u>Native sequence</u></b>	G8 of the recombinant protein is equivalent to G2 of human FGR
<b><u>Accession number</u></b>	GenBank M19722

#### **Recombinant FGR amino acid sequence:**

```

1 MHHHHHHCYV FCKKLEPVAT AKEDAGLEGD FRSYGAADHY GPDPTKARPA SSFAHIPNYS
61 NFSSQAINPG FLDSGTIRGV SGIGVTLFIA LYDYEARTED DLTFTKGEKF HILNNTEGDW
121 WEARSLSSGK TGCIPSNYVA PVDSIQAEW YFGKIGRKDA ERQLSPGNP QGAFLIRESE
181 TTKGAYLSLI RDWDQTRGDH VKHYKIRKLD MGGYYITTRV QFNSVQELVQ HYMEVNDGLC
241 NLLIAPCTIM KPQTLGLAKD AWEISRSSIT LERRLTGCF GDVWLGTWNG STKVAVKTLK
301 PGTMSPKAFL EEAQVMKLLR HDKLVQLYAV VSEPIYIVT EFMCHGSLLD FLKNPEGQDL
361 RLPQLVDMAA QVAEGMAYME RMNYIHRDLR AANILVGERL ACKIADFGLA RLIKDDEYNP
421 CQGSKFPIKW TAPEAALFGR FTIKSDVWSF GILLTELITK GRIPYPGMNK REVLEQVEQG
481 YHMPCPPGCP ASLYEAMEQT WRLDPEERPT FEYLQSFLED YFTSAEPQYQ PGDQT
  
```

#### **Recombinant FGR nucleotide sequence:**

```

1 atgcatcacc atcaccatca tggctgtgtg ttctgcaaga aattggagcc ggtggccacc
61 gccaaaggagg atgctggcct ggaaggggac ttcagaagct acggggcagc agaccactat
121 gggcctgacc ccactaaggc ccggcctgca tcctcatttg cccacatccc caactacagc
181 aacttctcct ctcaggccat caaccctggc ttccttgata gtggcaccat caggggtgtg
241 tcagggattg gggtgaccct gttcattgcc ctgtatgact atgaggctcg aactgaggat
301 gacctcacct tcaccaaggg cgagaagttc cacatcctga acaatactga aggtgactgg
361 tgggaggctc ggtctctcag ctccgaaaaa actggctgca ttcccagcaa ctacgtggcc
421 cctgttgact caatccaagc tgaagagtgg tactttggaa agattgggag aaaggatgca
481 gagaggcagc tgctttcacc aggcaacccc cagggggcct ttctcattcg ggaaagcgag
541 accaccaaag gtgcctactc cctgtccatc cgggactggg atcagaccag aggcgatcat
601 gtgaagcatt acaagatccg caaactggac atgggcggct actacatcac cacacggggt
661 cagttcaact cggtgcagga gctggtgcag cactacatgg aggtgaatga cgggctgtgc
721 aacctgctca tcgcccctg caccatcatg aagccgcaga cgctgggctt ggccaaggac
781 gcctgggaga tcagccgag ctccatcacg ctggagcgcc ggctgggcac cggctgcttc
841 ggggatgtgt ggctgggcac gtggaacggc agcactaagg tggcggtgaa gacgctgaag
901 ccgggcacca tgtccccgaa ggccttcctg gaggaggcgc aggtcatgaa gctgctgcgg
961 cacgacaagc tggtcagct gtacgcctg gtgtcggagg agcccatcta catcgtgacc
1021 gaggatcatgt gtcacggcag cttgctggat tttctcaaga acccagaggg ccaggatttg
1081 aggtgcccc aattggtgga catggcagcc caggtagctg agggcatggc ctacatggaa
1141 cgatgaact acattcaccg cgacctgagg gcagccaaca tcctggttgg ggagcggctg
1201 gcgtgcaaga tcgagactt tggcttggcg cgtctcatca aggacgatga gtacaacccc
1261 tgccaagggt ccaagttccc catcaagtgg acagcccag aagctgccct ctttggcaga
1321 tcaccatca agtcagact gtggtcctt gggatcctgc tactgagct catcacaag
1381 ggccgaatcc cctaccagc catgaataaa cgggaagtgt tggaacaggt ggagcagggc
1441 taccatgc cgtgccctcc aggctgcca gcatccctgt acgaggccat ggaacagacc
1501 tggcgtctgg acccggagga gaggcctacc ttcgagtacc tgcagtcctt cctggaggac
1561 tacttcacct ccgctgaacc acagtaccag cccggggatc agacatag
  
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.